Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer

M.K. Greene, T. Chen, E. Robinson, N.L. Straubinger, C. Minx, D.K.W. Chan, J. Wang, J.F. Burrows, S. Van Schaeybroeck, J.R. Baker, S. Caddick, D.B. Longley, D.E. Mager, R.M. Straubinger, V. Chudasama, C.J. Scott

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBritish Journal of Cancer
DOIs
Publication statusPublished - 11 Sep 2020

Cite this